ChAd63-KH

PREV_PKDL

at a glance

TARGET DISEASE

Visceral Leishmaniasis & Post kala azar dermal Leishmaniasis

TIMELINE

01 April 2018 to 31 December 2025

COORDINATOR

European Vaccine Initiative

FUNDER

EDCTP2

FUNDING

8 Mio Euro

SUMMARY

Clinical development of a prophylactic vaccine for prevention of visceral / post kala azar dermal leishmaniasis

The PREV_PKDL project aims at advancing the clinical development of ChAd63-KH vaccine for the prevention of visceral leishmaniasis (VL) / post kala azar dermal leishmaniasis (PKDL). The ChAd63-KH vaccine will be evaluated in healthy Sudanese volunteers aged 12-17 years in a safety, immunogenicity and efficacy phase Ib/II clinical trial. The results of this trial will be decisive in the future development of the ChAd63-KH vaccine.

Additionally, to better understand the disease as well as drug and vaccine responses, multidimensional, multiparameter phenotyping will be conducted on patient cohorts recruited across the countries of the Leishmaniasis East Africa Platform (LEAP; Ethiopia, Kenya, Sudan and Uganda). A major aim of PREV_PKDL project is to support LEAP in its ambitions, by extending its research capacity in immunology and vaccine development. This will be achieved through a program to strengthen immunology research capacity through the development of a flow cytometry network across LEAP. This capacity strengthening will help LEAP to develop as a major force for research and training on poverty-related neglected diseases in the East African Region.

PREV_PKDL

PARTNERS

European Vaccine Initiative (EVI) (Germany); Institute of Endemic Diseases (IEND) (Sudan); Kenya Medical Research Institute (KEMRI) (Kenya); Makerere University (Uganda); University of Gondar (Ethiopia); University of York (UK).

EU_Logo.png

I'm a paragraph. Click here to add your own text and edit me. It's easy.